Human complement component C3 N-glycome changes in type 1 diabetes complications

Changes in N-glycosylation have been described in numerous diseases and are being considered as biomarkers of ongoing pathological condition. Previous studies demonstrated the interrelation of N-glycosylation and type 1 diabetes (T1D), particularly linking serum N-glycan changes with complications a...

Full description

Saved in:
Bibliographic Details
Published in:Frontiers in endocrinology (Lausanne) Vol. 14; p. 1101154
Main Authors: Šoić, Dinko, Štambuk, Jerko, Tijardović, Marko, Keser, Toma, Lauc, Gordan, Bulum, Tomislav, Lovrenčić, Marijana Vučić, Rebrina, Sandra Vučković, Tomić, Martina, Novokmet, Mislav, Smirčić-Duvnjak, Lea, Gornik, Olga
Format: Journal Article
Language:English
Published: Switzerland Frontiers Media S.A 24.05.2023
Subjects:
Albuminuria - etiology
complement component (C3)
Diabetes Mellitus, Type 1 - complications
Diabetic Retinopathy - complications
Endocrinology
Glycopeptides
Humans
LC-MS
Middle Aged
N-glycosylation
Polysaccharides
type 1 diabetes complications
LC-MS
glycopeptides
type 1 diabetes complications
complement component (C3)
N-glycosylation
ISSN:1664-2392, 1664-2392
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Changes in N-glycosylation have been described in numerous diseases and are being considered as biomarkers of ongoing pathological condition. Previous studies demonstrated the interrelation of N-glycosylation and type 1 diabetes (T1D), particularly linking serum N-glycan changes with complications accompanying the disease. Moreover, the role of complement component C3 in diabetic nephropathy and retinopathy has been implicated, and C3 N-glycome was found to be altered in young T1D patients. Therefore, we investigated associations between C3 N-glycan profiles and albuminuria and retinopathy accompanying T1D, as well as glycosylation connection with other known T1D complication risk factors. Complement component C3 N-glycosylation profiles have been analyzed from 189 serum samples of T1D patients (median age 46) recruited at a Croatian hospital centre. Using our recently developed high-throughput method, relative abundances of all six of the C3 glycopeptides have been determined. Assessment of C3 N-glycome interconnection with T1D complications, hypertension, smoking status, estimated glomerular filtration rate (eGFR), glycaemic control and duration of the disease was done using linear modelling. Significant changes of C3 N-glycome in severe albuminuria accompanying type 1 diabetes were observed, as well as in T1D subjects with hypertension. All except one of the C3 glycopeptides proved to be associated with measured HbA1c levels. One of the glycoforms was shown to be changed in non-proliferative T1D retinopathy. Smoking and eGFR showed no effect on C3 N-glycome. Furthermore, C3 N-glycosylation profile was shown to be independent of disease duration. This study empowered the role of C3 N-glycosylation in T1D, showing value in distinguishing subjects with different diabetic complications. Being independent of the disease duration, these changes may be associated with the disease onset, making C3 N-glycome a potential novel marker of the disease progression and severity.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Reviewed by: Akira Sugawara, Tohoku University, Japan; Robin Lindsay, Uppsala University, Sweden
Edited by: Gustaf Christoffersson, Uppsala University, Sweden
ISSN:1664-2392
1664-2392
DOI:10.3389/fendo.2023.1101154